Journal Mobile Options
Table of Contents
Vol. 129, No. 3, 2002
Issue release date: November 2002
Section title: Original Paper
Int Arch Allergy Immunol 2002;129:219–227
(DOI:10.1159/000066778)

Factors Regulating the Effect of IL-4 on Intestinal Epithelial Barrier Function

Di Leo V. · Yang P.-C. · Berin M.C. · Perdue M.H.
Intestinal Disease Research Programme, McMaster University, Hamilton, Ont., Canada

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/14/2002
Published online: 11/29/2002
Issue release date: November 2002

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Inflammatory bowel disease is associated with an imbalance in cytokine production and defective intestinal barrier function. Previous studies indicate that IL-4, a cytokine increased in food allergy and in early Crohn’s disease, enhances epithelial permeability. Here, we characterized the mechanism of action of IL-4 on cultured epithelial cells and examined if the anti-inflammatory cytokines, TGF-β or IL-10, can modulate the effects of IL-4. Methods: Confluent monolayers of human T84 epithelial cells were cultured with IL-4 alone or in combination with IL-10 or TGF-β or with inhibitors of protein synthesis and blockers of IL-4 receptor signalling pathways. Permeability was evaluated by measuring transepithelial resistance (TER), flux of 3H-fMLP (a small bacterial tripeptide) and horseradish peroxidase (HRP) (a macromolecule). Results: T84 cells cultured with IL-4 showed a significant drop in TER as well as an increased flux of 3H-fMLP and HRP. Co-treatment with IL-10 did not improve TER, whereas TGF-β attenuated the resistance drop. However, neither TGF-β nor IL-10 were able to correct the increased 3H-fMLP flux. In contrast, the increased HRP flux caused by IL-4 was inhibited by both IL-10 and TGF-β. TGF-β and IL-10 significantly reduced IL-4-enhanced values for endosomal area and paracellular spaces containing HRP. Inhibitor studies indicated the requirement for protein synthesis and the involvement of phosphatidylinositol 3-kinase. Conclusions: These results provide new insights into the regulation of intestinal barrier function and may suggest a novel approach in the treatment of intestinal inflammation.

© 2002 S. Karger AG, Basel


  

Author Contacts

Correspondence to: Dr. M. Perdue
HSC-3N5C, McMaster University
1200 Main Street West, Hamilton, Ont. L8N3Z5 (Canada)
Tel. +1 905 525 9140/ext. 22585, Fax +1 905 522 3454
E-Mail perdue@mcmaster.ca

  

Article Information

Received: Received: October 8, 2001
Accepted after revision: August 14, 2002
Number of Figures : 4, Number of Tables : 3, Number of References : 38

  

Publication Details

International Archives of Allergy and Immunology
Founded 1950

Vol. 129, No. 3, Year 2002 (Cover Date: November 2002)

Journal Editor: D. Kraft, Vienna
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information:http://www.karger.com/journals/iaa


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/14/2002
Published online: 11/29/2002
Issue release date: November 2002

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.